Sanofi Genzyme News |

Featured Press Releases

September 15, 2018
Positive Phase 3 results presented for Dupixent® (dupilumab) show significant improvement on multiple measures of disease severity in adolescents with moderate-to-severe atopic dermatitis
Detailed results from a pivotal Phase 3 trial showed Dupixent® (dupilumab) monotherapy demonstrated a significant improvement in signs and symptoms of atopic dermatitis and certain quality of life measures in adolescent patients (12-17 years) with moderate-to-severe atopic dermatitis, whose disease was...
September 3, 2018
Cablivi™ (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
The European Commission has granted marketing authorization for Cablivi™ (caplacizumab) for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood-clotting disorder. Cablivi is the first therapeutic specifically indicated for the treatment of aTTP.
July 18, 2018
Sanofi and REVOLUTION Medicines Launch Global Partnership to Develop Potential First-in-Class Targeted Treatments for Multiple Cancers
Sanofi and REVOLUTION Medicines, Inc. today announced an exclusive worldwide partnership to develop and commercialize targeted therapies, based on the biology of the cellular enzyme SHP2, for patients with non-small lung cancer and other types of cancer carrying certain mutations. This...
June 4, 2018
New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma
The New England Journal of Medicine (NEJM) today published pivotal data from two trials evaluating cemiplimab in advanced cutaneous squamous cell carcinoma (CSCC). The results were also presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. Advanced CSCC, the deadliest...

Leadership

Bill Sibold
Executive Vice President and Head of Sanofi Genzyme
Bill joined Sanofi Genzyme in 2011 as Senior Vice President and Head of Multiple Sclerosis, and oversaw the successful launches of its two MS treatments. As Head of Sanofi Genzyme, he leads the business’s efforts to maintain its leadership in rare diseases while continuing to grow in multiple sclerosis, oncology and immunology. More...

Tweets

September is #ProstateCancer Awareness Month. Find out how you can get involved https://t.co/OLaz0HBHzU @PCFnews https://t.co/mDhGrcCUtp-26 min 8 sec ago

RT @Bioverativ: Just a few weeks until the @NHF_Hemophilia Annual Bleeding Disorders Conference! We’re looking forward to seeing ol… https://t.co/jvaM0amFKE-12 hours 56 min ago

#DidYouKnow having a father or brother with #ProstateCancer more than doubles a man’s risk of developing the diseas… https://t.co/426mlWe3th-1 day 21 hours ago

Thank you to everyone who watched or shared our #ChangeAD video. You contributed to greater awareness of… https://t.co/3mbbDDplHO-2 days 21 hours ago

What do certain diseases of the nose, skin, lungs and esophagus have in common? The answer may be Type 2… https://t.co/fLouCvfyxs-2 days 23 hours ago

Search Newsroom

Featured Press Releases

Featured Videos

Leadership

Media Resources

Tweets

Social Media